Rosa Terracciano

Prof. Rosa Terracciano

Department of Experimental and Clinical Medicine, Magna Graecia University, Salvatore Venuta University Campus, Catanzaro, Italy

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2006 in Current Opinion in Chemical Biology
Verified
Journal Article
Closed access
MCMark Ming-Cheng Cheng
Mark Ming-Cheng Cheng
Giovanni CudaGiovanni Cuda
Giovanni Cuda
YBYuri L Bunimovich
Yuri L Bunimovich
Marco GaspariMarco Gaspari
Marco Gaspari
JHJames R Heath
James R Heath
MFMauro Ferrari
Mauro Ferrari

1 September 2013 in Osteoarthritis and Cartilage
Verified
Journal Article
Closed access
LGL. Gallelli
L. Gallelli
Olimipio GalassoOlimipio Galasso
Olimipio Galasso
DFD. Falcone
D. Falcone
SSS. Southworth
S. Southworth
Marta GrecoMarta Greco
Marta Greco
GSGiovambattista De Sarro
Giovambattista De Sarro

24 May 2006 in Proteomics
Verified
Journal Article
Closed access
PDF file
Rosa TerraccianoRosa Terracciano
Rosa Terracciano
Marco GaspariMarco Gaspari
Marco Gaspari
FTFlaviano Testa
Flaviano Testa
Luigi PasquaLuigi Pasqua
Luigi Pasqua
PTPierosandro Tagliaferri
Pierosandro Tagliaferri
SVSalvatore Venuta
Salvatore Venuta

Verified
Journal Article
Open access
PDF file
Corrado PelaiaCorrado Pelaia
Corrado Pelaia
GPGiulia Pelaia
Giulia Pelaia
Claudia CrimiClaudia Crimi
Claudia Crimi
AMAngelantonio Maglio
Angelantonio Maglio
Luca GallelliLuca Gallelli
Luca Gallelli
Alessandro VatrellaAlessandro Vatrella
Alessandro Vatrella
Thymic stromal lymphopoietin (TSLP) is an innate cytokine, belonging to the group of alarmins, which plays a key pathogenic role in asthma by acting as an upstream activator of cellular and molecular pathways leading to type 2 (T2-high) airway inflammation. Released from airway epithelial cells upon tissue damage induced by several noxious agents including allergens, viruses, bacteria, and airborne pollutants, TSLP activates dendritic cells and group 2 innate lymphoid cells involved in the pathobiology of T2-high asthma. Tezepelumab is a fully human monoclonal antibody that binds to TSLP, thereby preventing its interaction with the TSLP receptor complex. Preliminary results of randomized clinical trials suggest that tezepelumab is characterized by a good safety and efficacy profile in patients with severe, uncontrolled asthma.

10 October 2012 in Cell Proliferation
Verified
Journal Article
Closed access
PDF file
GPGirolamo Pelaia
Girolamo Pelaia
Luca GallelliLuca Gallelli
Luca Gallelli
TRT. Renda
T. Renda
DFD. Fratto
D. Fratto
DFD. Falcone
D. Falcone
RSRocco Savino
Rocco Savino

Verified
Journal Article
Open access
PDF file
RSRocco Savino
Rocco Savino
SPSergio Paduano
Sergio Paduano
MPMariaimmacolata Preianò
Mariaimmacolata Preianò
Rosa TerraccianoRosa Terracciano
Rosa Terracciano
In the modern process of drug discovery, clinical, functional and chemical proteomics can converge and integrate synergies. Functional proteomics explores and elucidates the components of pathways and their interactions which, when deregulated, lead to a disease condition. This knowledge allows the design of strategies to target multiple pathways with combinations of pathway-specific drugs, which might increase chances of success and reduce the occurrence of drug resistance. Chemical proteomics, by analyzing the drug interactome, strongly contributes to accelerate the process of new druggable targets discovery. In the research area of clinical proteomics, proteome and peptidome mass spectrometry-profiling of human bodily fluid (plasma, serum, urine and so on), as well as of tissue and of cells, represents a promising tool for novel biomarker and eventually new druggable targets discovery. In the present review we provide a survey of current strategies of functional, chemical and clinical proteomics. Major issues will be presented for proteomic technologies used for the discovery of biomarkers for early disease diagnosis and identification of new drug targets.